Finance

Lists
Why is RLMD down 5,75%?
Dive Deeper
RLMD:NASDAQ
Relmada Therapeutics Inc
3,28 USD
-5,75%
(-0,20) 1D
3,28 USD
0,00% (0,00)
After hours
Closed: 6-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RLMD...
Open
3,50 USD
High
3,50 USD
Low
3,26 USD
Mkt. cap
361,94 млн
Avg. vol.
1,18 млн
Volume
1,73 млн
52-wk high
8,00 USD
52-wk low
1,80 USD
EPS
-0,96 USD
Beta
0,51
Shares outstanding
106,67 млн
No. of employees
17
Open
3,50 USD
High
3,50 USD
Low
3,26 USD
Mkt. cap
361,94 млн
Avg. vol.
1,18 млн
Volume
1,73 млн
52-wk high
8,00 USD
52-wk low
1,80 USD
EPS
-0,96 USD
Beta
0,51
Shares outstanding
106,67 млн
No. of employees
17
News stories
From web sources and news partners
About Relmada Therapeutics Inc
CEO-
Employees17
Founded2004
HeadquartersКорал Гейблс, Флорида, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websiterelmada.com
Analyst ratings
Based on 2 analysts giving stock ratings to RLMD in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for RLMD in the last 3 months.
Highest
Current 3,28 USD
12,00 USD (+265,85%)
Average
12,00 USD (+265,85%)
Lowest
12,00 USD (+265,85%)
Analyst
Recommendation
Action
Price target
Projected
Date
Uy Ear
Mizuho Securities
Buy
Reiterated
19,00 USD
+479,3%
08/11/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
12,00 USD
+265,9%
08/10/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
12,00 USD
+265,9%
08/07/2026
Christopher Liu
Lucid Capital
Buy
Initiated
14,00 USD
+326,8%
03/02/2026
Last report
2022-ж., 10-ноя.
Fiscal period
Q3 2022
EPS / Est. (USD)
-1,26 USD / -1,47 USD
+14,22%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q3 2022 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4,04 млн
5,17 млн
8,09 млн
8,39 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,29 млн
12,26 млн
11,37 млн
6,62 млн
Operating expense
10,33 млн
17,43 млн
19,46 млн
15,01 млн
Total operating expenses
10,33 млн
17,43 млн
19,46 млн
15,01 млн
Operating income
-10,33 млн
-17,43 млн
-19,46 млн
-15,01 млн
Other non operating income
-
-
-
-
EBT including unusual items
-10,09 млн
-19,87 млн
-19,05 млн
-12,91 млн
EBT excluding unusual items
-10,08 млн
-17,05 млн
-18,50 млн
-12,71 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10,09 млн
-19,87 млн
-19,05 млн
-12,91 млн
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
247,01 миң
387,23 миң
959,76 миң
2,30 млн
Interest expense
-
-
-
-
Net interest expenses
247,01 миң
387,23 миң
959,76 миң
2,30 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору